1. Signaling Pathways
  2. PROTAC
  3. Ligand for Target Protein for PROTAC

Ligand for Target Protein for PROTAC

The PROTAC molecule consists of a ligand, which binds the target protein, connected by a linker to another ligand that binds the E3 ubiquitin ligase.

The association between a protein and an E3 ligase, as induced by a PROTAC molecule, will lead to the transfer of ubiquitin and degradation of the targeted protein.

Ligand for Target Protein for PROTAC Related Products (41):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13030
    (+)-JQ-1 1268524-70-4 99.90%
    (+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy.
    (+)-JQ-1
  • HY-13001
    Quizartinib 950769-58-1 99.34%
    Quizartinib (AC220) is a potent Flt3 tyrosine kinase inhibitor with a Kd of 1.6 nM. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.
    Quizartinib
  • HY-107443
    I-BET762 carboxylic acid 1300019-38-8
    I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC50 of 5.1.
    I-BET762 carboxylic acid
  • HY-107451
    PROTAC BET-binding moiety 1 2093387-77-8
    PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors.
    PROTAC BET-binding moiety 1
  • HY-43723
    PROTAC BET-binding moiety 2 916493-82-8 99.30%
    PROTAC BET-binding moiety 2 is an inhibitor of BET bromodomain.
    PROTAC BET-binding moiety 2
  • HY-126534A
    CDK ligand for PROTAC hydrochloride 99.01%
    CDK ligand for PROTAC hydrochloride is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.
    CDK ligand for PROTAC hydrochloride
  • HY-44432
    Navitoclax-piperazine 2143096-93-7
    Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).
    Navitoclax-piperazine
  • HY-129603
    SI-109
    SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36.
    SI-109
  • HY-111606
    DUPA 302941-52-2 >98.0%
    DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells.
    DUPA
  • HY-44103
    Desmethyl-QCA276 2126819-55-2
    Desmethyl-QCA276, the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC50 of 10 nM, and with a Ki of 2.3 nM.
    Desmethyl-QCA276
  • HY-107445
    PROTAC BRD9-binding moiety 1 2097512-23-5
    PROTAC BRD9-binding moiety 1 is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.
    PROTAC BRD9-binding moiety 1
  • HY-44012A
    SMARCA-BD ligand 1 for Protac dihydrochloride 2369053-68-7
    SMARCA-BD ligand 1 for Protac dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
    SMARCA-BD ligand 1 for Protac dihydrochloride
  • HY-124625
    BI-4464 1227948-02-8 98.34%
    BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC.
    BI-4464
  • HY-12863B
    CPI-0610 carboxylic acid 1380089-81-5
    CPI-0610 carboxylic acid is a ligand for target protein for PROTACT. CPI-0610 carboxylic acid is a potent bromodomain and extra-terminal (BET) protein inhibitor。 CPI-0610 carboxylic acid has the potential in the therapy of multiple myeloma.
    CPI-0610 carboxylic acid
  • HY-44012
    SMARCA-BD ligand 1 for Protac 1997319-92-2
    SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
    SMARCA-BD ligand 1 for Protac
  • HY-111847
    Androstanolone acetate 1164-91-6
    Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to cIAP1 ligand Bestatin via a linker to form PROTACs.
    Androstanolone acetate
  • HY-107447
    N-Deshydroxyethyl Dasatinib 910297-51-7
    N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.
    N-Deshydroxyethyl Dasatinib
  • HY-130813
    BET-IN-6
    BET-IN-6 is a potent and high affnity BRD2/BRD4 inhibitor. BET-IN-6 is the ligand for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612).
    BET-IN-6
  • HY-130848
    MEK1/2-IN-1
    MEK1/2-IN-1 (compound 16), a dual MEK1 and MEK2 inhibitor, is the ligand for the PROTAC product MS432 (HY-13060) and MS432N.
    MEK1/2-IN-1
  • HY-125908
    A-1210477-piperazinyl 2351218-72-7
    A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (MCL1) used for PROTAC technology.
    A-1210477-piperazinyl
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.